Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

SEC Filings

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
Filing date Form Description View
Nov 1, 2022 8-K

Report of unscheduled material events or corporate event

0001808805-22-000107.pdf
0001808805-22-000107.rtf
0001808805-22-000107.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Nov 1, 2022 8-K/A

Amendment to a previously filed 8-K

0001808805-22-000108.pdf
0001808805-22-000108.rtf
0001808805-22-000108.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Nov 1, 2022 10-Q

Quarterly report which provides a continuing view of a company's financial position

0001628280-22-027552.pdf
0001628280-22-027552.rtf
0001628280-22-027552.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Sep 28, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000101.pdf
0001808805-22-000101.rtf
0001808805-22-000101.xls
View HTML
Sep 26, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000099.pdf
0001808805-22-000099.rtf
0001808805-22-000099.xls
View HTML
Sep 19, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000097.pdf
0001808805-22-000097.rtf
0001808805-22-000097.xls
View HTML
Aug 22, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000095.pdf
0001808805-22-000095.rtf
0001808805-22-000095.xls
View HTML
Aug 16, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000093.pdf
0001808805-22-000093.rtf
0001808805-22-000093.xls
View HTML
Aug 9, 2022 424B3

Form of prospectus reflecting facts events constituting substantive change from last form

0001808805-22-000091.pdf
0001808805-22-000091.rtf
0001808805-22-000091.xls
View HTML
Aug 8, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000089.pdf
0001808805-22-000089.rtf
0001808805-22-000089.xls
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Displaying 1 - 10 of 162 results

Data provided by Kaleidoscope.

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.

Privacy Policy | Terms